Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Hydrocodone | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Magnesium sulfate | The therapeutic efficacy of Psilocybin can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Psilocybin may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Mirtazapine | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Orphenadrine | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Pramipexole | Psilocybin may increase the sedative activities of Pramipexole. |
| Ropinirole | Psilocybin may increase the sedative activities of Ropinirole. |
| Rotigotine | Psilocybin may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Psilocybin. |
| Sodium oxybate | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Thalidomide | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Psilocybin. |
| Ethanol | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Psilocybin may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Zimelidine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Psilocybin is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Psilocybin is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Psilocybin is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Psilocybin is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Psilocybin is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Psilocybin is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Psilocybin. |
| Indalpine | The risk or severity of adverse effects can be increased when Psilocybin is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Psilocybin is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Psilocybin is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Psilocybin. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Psilocybin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Psilocybin is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Psilocybin. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Psilocybin. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Psilocybin. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Psilocybin. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Psilocybin. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Psilocybin. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Psilocybin. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Psilocybin. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Psilocybin. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Psilocybin. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Psilocybin. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Psilocybin. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Psilocybin. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Psilocybin. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Psilocybin. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Psilocybin. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Psilocybin. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Psilocybin. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Psilocybin. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Psilocybin. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Psilocybin. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Psilocybin. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Psilocybin. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Psilocybin. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Psilocybin. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Psilocybin. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Psilocybin. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with Psilocybin. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Psilocybin. |
| Metocurine iodide | The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Psilocybin. |
| Secobarbital | The risk or severity of CNS depression can be increased when Secobarbital is combined with Psilocybin. |
| Methocarbamol | The risk or severity of CNS depression can be increased when Methocarbamol is combined with Psilocybin. |
| Triprolidine | The risk or severity of CNS depression can be increased when Triprolidine is combined with Psilocybin. |
| Meperidine | The risk or severity of CNS depression can be increased when Meperidine is combined with Psilocybin. |
| Metharbital | The risk or severity of CNS depression can be increased when Metharbital is combined with Psilocybin. |
| Quinine | The risk or severity of CNS depression can be increased when Quinine is combined with Psilocybin. |
| Methohexital | The risk or severity of CNS depression can be increased when Methohexital is combined with Psilocybin. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Psilocybin. |
| Entacapone | The risk or severity of CNS depression can be increased when Entacapone is combined with Psilocybin. |
| Oxycodone | The risk or severity of CNS depression can be increased when Oxycodone is combined with Psilocybin. |
| Dextromethorphan | The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Psilocybin. |
| Mephenytoin | The risk or severity of CNS depression can be increased when Mephenytoin is combined with Psilocybin. |
| Cisatracurium | The risk or severity of CNS depression can be increased when Cisatracurium is combined with Psilocybin. |
| Fenfluramine | The risk or severity of CNS depression can be increased when Fenfluramine is combined with Psilocybin. |
| Mazindol | The risk or severity of CNS depression can be increased when Mazindol is combined with Psilocybin. |
| Fluticasone propionate | The risk or severity of CNS depression can be increased when Fluticasone propionate is combined with Psilocybin. |
| Lisuride | The risk or severity of CNS depression can be increased when Lisuride is combined with Psilocybin. |
| Ethosuximide | The risk or severity of CNS depression can be increased when Ethosuximide is combined with Psilocybin. |
| Thiopental | The risk or severity of CNS depression can be increased when Thiopental is combined with Psilocybin. |
| Cisapride | The risk or severity of CNS depression can be increased when Cisapride is combined with Psilocybin. |
| Butorphanol | The risk or severity of CNS depression can be increased when Butorphanol is combined with Psilocybin. |